יחס חוב לטווח ארוך להון Sana Corp (SANA)

Sana Biotechnology (SANA) is pioneering the field of genetic design by creating immune-evasive cells to treat oncology and diabetes. The company's production capacities are currently being modernized through the automation of gene editing, and the price trajectory of the shares shown below on GURU.Markets reflects a metric of 0.39. The success of hypoimmune methods will allow the firm to capture a unique segment and establish its own pricing power.

To select assets with a high margin of fundamental strength, it is critical to evaluate the long-term debt-to-equity ratio, which determines the stability of the liability structure. This long-term debt-to-equity ratio measures the reliance of Sana Biotechnology (SANA) on borrowed funds in the absence of operating profit, demonstrating how effectively investment capital covers long-term loans during the clinical trial stage.